Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Trial of NV-HHV-101 forTtopical Dermal Treatment of the Shingles Rash

Next Previous
X
Search
Trial Profile

A Phase I Clinical Trial of NV-HHV-101 forTtopical Dermal Treatment of the Shingles Rash

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NV HHV 101 (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions
  • Sponsors NanoViricides

    • Most Recent Events

    • 09 Jan 2020 According to a NanoViricides media release, the company has successfully completed genetic toxicology testing required to support the IND application for NV-HHV-101 moving towards this human clinical trial.
    • 07 Jan 2020 According to a NanoViricides media release, after receiving all of the reports from the various required IND-enabling studies, the Company anticipates filing an IND with the US FDA to advance NV-HHV-101 into this trial for topical dermal treatment of the shingles rash as the initial indication.
    • 10 Jun 2019 According to a NanoViricides media release, the company has received favorable response from the US FDA on the Company's pre-IND application for NV-HHV-101 with the first indication of shingles rash (VZV).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top